PharmaWatch: Diabetes Treatment Leader Novo Nordisk Eyes China as Critical Market

Mar 1, 2019 | China, Diabetes, Leading Pharma, Novo Nordisk

XinhuaNet reports that Novo Nordisk, a market leader in diabetes drugs, sees China as a high priority moving forward. Based on its aging population and ongoing reforms, the Danish drug maker see enormous opportunity for growth. Driving trends include:

  • Ongoing medical reforms
  • Modernizing regulatory regime
  • Chinese demographics (aging, etc.)
  • Growing urbanization and wealthy lifestyle
  • Growing middle class
  • Unbalanced lifestyles

According to the International Diabetes Association, over 110 million in China face diabetes reports Xinhuanet. Novo Nordisk first set up its China operations 25 years ago. Since then, they have steadily expanded presence not only in manufacturing but in R&D. Novo Nordisk China President, Christine Zhou, reports Chinese governments at all levels attach great importance to diabetes treatment and education. Public awareness is rising, but there is still much work to do given the size of the potential patients.”


Pin It on Pinterest